Disease relevance of Radiation Oncology

• High-risk Merkel cell carcinoma of the skin treated with synchronous carboplatin/etoposide and radiation: a Trans-Tasman Radiation Oncology Group Study--TROG 96:07 [1].
• PURPOSE: To select one of two chemoradiotherapy regimens for locally advanced squamous cell carcinoma (SCC) of the head and neck as the experimental arm for the next Trans-Tasman Radiation Oncology Group phase III trial [2].
• METHODS AND MATERIALS: Chart records of patients with invasive breast cancer managed with breast-conserving therapy (BCT) at the therapeutic radiology facilities of Yale University School of Medicine before 2001 were reviewed [3].
• Analysis of toxicity of Merkel cell carcinoma of the skin treated with synchronous carboplatin/etoposide and radiation: a Trans-Tasman Radiation Oncology Group study [4].
• PURPOSE: To quantitate the impact of a number of variables within the American Society of Therapeutic Radiology and Oncology consensus definition (ACD) of biochemical failure (bF) for prostate cancer [5].

High impact information on Radiation Oncology

• The American Society of Therapeutic Radiology and Oncology Consensus Group definition of prostate-specific antigen (PSA) relapse-free survival (RFS) was used with the added caveat of an absolute increase of >/= 1.0 ng/mL [6].
• Poly(ADP-ribose) polymerase in DNA damage-response pathway: implications for radiation oncology [7].
• The American Radium Society. Radiation oncology in the 3rd millennium [8].
• RESULTS: ACR professional standards are widely used, particularly those for mammography and radiation oncology [9].
• PURPOSE: To examine the impact of detection biases on three prostate cancer biochemical failure (bF) definitions in comparison with the existing American Society for Therapeutic Radiology and Oncology Consensus Definition (ACD) [10].

Chemical compound and disease context of Radiation Oncology

• Fifteen patients with juvenile nasopharyngeal angiofibroma (JNA) were treated in the Department of Radiation Oncology, Baylor College of Medicine between 1973 and 1986 [11].
• This paper presents a review of 21 cases of primary gastro-intestinal lymphoma seen at the Department of Radiation Oncology, Christian Medical College, Vellore, during the period 1979-1986 [12].
• Acute symptoms, not rectally administered sucralfate, predict for late radiation proctitis: longer term follow-up of a phase III trial--Trans-Tasman Radiation Oncology Group [13].
• Between 1972 and 1985, 82 Classic Kaposi's Sarcomas were treated by radiotherapy in the Division of Radiation Oncology at NYU Medical Center. Doses ranged from 650 cGy in 1 fraction to 3,500 cGy in 10 fractions, reflecting the judgement of the responsible physician [14].
• METHODS AND MATERIALS: In 1983, the Departments of Radiation Oncology and Ophthalmology at the Clínica Puerta de Hierro, Madrid, Spain, initiated a clinical study using removable episcleral iridium-192 wires in the treatment of choroidal melanoma [15].

Biological context of Radiation Oncology

• METHODS AND MATERIALS: Between 1974 and 1990, 164 patients were evaluated by members of Yale University School of Medicine departments of Dermatology and Therapeutic Radiology and treated with total skin electron beam therapy to a total dose of 3600 cGy [16].
• The breast cancer susceptibility genes, BRCA1 and BRCA2, are used to illustrate the application of molecular biology to clinical radiation oncology [17].
• SETTING: The Departments of Otolaryngology and Oncology and the Radiation Oncology Research Unit at Queen's University in Kingston, Ontario. METHODS: Five hundred and ninety-four patients with cancer of the head and neck classified by TNM and TANIS were analyzed for the outcome dead of disease using estimates of relative risk [18].

Associations of Radiation Oncology with chemical compounds

• Implementing IMRT in clinical practice: a joint document of the American Society for Therapeutic Radiology and Oncology and the American Association of Physicists in Medicine [19].
• These studies strengthen the argument for subcutaneous administration of amifostine in radiation oncology [20].
• PURPOSE: Selective high-dose radiation of solid tumors has been a goal of radiation oncology [21].
• This, in light of the fact that other well-tolerable hypoxic cell sensitizers such as nimorazole with clinically proven efficacy at daily oral doses of < 3 g are available, limits the potential usefulness of ISO for radiation oncology [22].
• Pentoxifylline (Ptx), a hemorrheologic methylxanthine derivative, is of interest in radiation oncology for several reasons [23].

Gene context of Radiation Oncology

• Molecular biology in radiation oncology. Radiation oncology perspective of BRCA1 and BRCA2 [17].
• CONCLUSIONS: These results suggest a role for COX-2 inhibitors in the normal tissue response to IR when administered at therapeutically achievable doses and therefore may have clinical implications for radiation oncology patients in the prevention of IR-induced malignancy [24].
• Biochemical relapse was defined as PSA levels >0.2 for RP cases and three consecutive rising PSA levels (American Society for Therapeutic Radiology Oncology consensus definition) for all other cases [25].
• Hyperthermia--the actual role in radiation oncology and future prospects. Part I [26].
• Erythropoietin in radiation oncology - A review. 1st international conference, Freiburg, June 11-12, 1999 [27].

Analytical, diagnostic and therapeutic context of Radiation Oncology

• Biochemical disease-free survival was defined by the American Society for Therapeutic Radiology and Oncology consensus definition with the additional constraint that the most recent PSA level was <or=1.0 ng/mL [28].
• International Clinical Trials in Radiation Oncology. Large field trials [29].
• METHODS AND MATERIALS: Between January 1, 1955, and August 2000, 576 patients with a diagnosis of nasopharyngeal carcinoma were seen at the department of radiation oncology, University of California-San Francisco, and 55 patients received intracavitary brachytherapy as one part of their treatment [30].
• Treatment failure was based on our modification of the American Society for Therapeutic Radiology and Oncology's (ASTRO) recommended failure criteria, defined as 3 consecutive serum Prostate Specific Antigen (PSA) rises (1) [31].
• This was a retrospective study of all newly diagnosed patients with NPC from the Singapore General Hospital and treated in the Department of Therapeutic Radiology in the year 1996 (1 January-31 December) [32].

References